UGT2B7 promoter variant-840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease

被引:62
作者
Darbari, Deepika S. [1 ,2 ]
van Schalk, Ron H. N. [3 ]
Capparelli, Edmund V. [4 ,5 ]
Rana, Sohail [6 ]
McCarter, Robert [7 ]
van den Anker, John [8 ,9 ]
机构
[1] Childrens Natl Med Ctr, Ctr Canc & Blood Dis, Washington, DC 20010 USA
[2] George Washington Univ, Sch Med & Hlth Sci, Dept Pediat, Washington, DC 20052 USA
[3] Erasmus MC, Dept Clin Chem, Rotterdam, Netherlands
[4] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA
[5] Univ Calif San Diego, Skaggss Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA
[6] Howard Univ, Coll Med, Dept Pediat & Child Hlth, Washington, DC USA
[7] Childrens Natl Med Ctr, Childrens Res Inst, Washington, DC 20010 USA
[8] Childrens Natl Med Ctr, Div Pediat Clin Pharmacol, Washington, DC 20010 USA
[9] George Washington Univ, Sch Med & Hlth Sci, Dept Physiol & Pharmacol, Washington, DC 20052 USA
关键词
D O I
10.1002/ajh.21051
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The purpose of the study was to determine if UDP-glucuronosyltransferase (UGT) 2B7 allelic variants encoding for UGT2B7, primary enzyme responsible for morphine glucuronidation contribute to the variability in the hepatic clearance of morphine in sickle cell disease (SCID). Twenty-four hour PK study of morphine and UGT2B7 variants genotyping was performed in 20 SCD patients in a steady state of health. Presence of the -840G allele (GG and GA) was associated with lower morphine metabolites/morphine AUC ratio compared with AA genotype (1.8 +/- 0.5 vs. 3.0 +/- 1.8 for M6G/M and 10.1 +/- 2.7 vs. 15.7 +/- 9.4 for M3G/M) (P = 0.03). Presence of UGT2B7 -840G allele is associated with significantly reduced glucuronidation of morphine and thus contributes to the variability in hepatic clearance of morphine in SCD.
引用
收藏
页码:200 / 202
页数:3
相关论文
共 10 条
[1]
Judging the effectiveness of analgesia for children and adolescents during vaso-occlusive events of sickle cell disease [J].
Beyer, JE .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2000, 19 (01) :63-72
[2]
COFFMAN BL, 1997, DRUG METAB DISPOS, V1, P1
[3]
INTRAVENOUS MORPHINE PHARMACOKINETICS IN PEDIATRIC-PATIENTS WITH SICKLE-CELL DISEASE [J].
DAMPIER, CD ;
SETTY, BNY ;
LOGAN, J ;
IOLI, JG ;
DEAN, R .
JOURNAL OF PEDIATRICS, 1995, 126 (03) :461-467
[4]
DEATH FROM A MORPHINE INFUSION DURING A SICKLE-CELL CRISIS [J].
GERBER, N ;
APSELOFF, G .
JOURNAL OF PEDIATRICS, 1993, 123 (02) :322-325
[5]
GRAVES DA, 1985, CLIN PHARMACY, V4, P41
[6]
Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene:: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients [J].
Holthe, M ;
Rakvåg, TN ;
Klepstad, P ;
Idle, JR ;
Kaasa, S ;
Krokan, HE ;
Skorpen, F .
PHARMACOGENOMICS JOURNAL, 2003, 3 (01) :17-26
[7]
Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease [J].
Kopecky, EA ;
Jacobson, S ;
Joshi, P ;
Koren, G .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (03) :140-146
[8]
OPIOID PHARMACOKINETICS IN RELATION TO THEIR EFFECTS [J].
MATHER, LE .
ANAESTHESIA AND INTENSIVE CARE, 1987, 15 (01) :15-22
[9]
ANALGESIA IN CHILDREN WITH SICKLE-CELL CRISIS - COMPARISON OF INTERMITTENT OPIOIDS VS CONTINUOUS INTRAVENOUS-INFUSION OF MORPHINE AND PLACEBO-CONTROLLED STUDY OF OXYGEN INHALATION [J].
ROBIEUX, IC ;
KELLNER, JD ;
COPPES, MJ ;
SHAW, D ;
BROWN, E ;
GOOD, C ;
OBRODOVICH, H ;
MANSON, D ;
OLIVIERI, NF ;
ZIPURSKY, A ;
KOREN, G .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1992, 9 (04) :317-326
[10]
Determination of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in plasma after intravenous and intrathecal morphine administration using HPLC with electrospray ionization and tandem mass spectrometry [J].
Slawson, MH ;
Crouch, DJ ;
Andrenyak, DM ;
Rollins, DE ;
Lu, JK ;
Bailey, PL .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1999, 23 (06) :468-473